Pheochromocytoma Market Size
The global pheochromocytoma market was valued at USD 2.16 billion in 2025 and is projected to reach USD 3.86 billion by 2033, growing at a CAGR of 8.5% during the forecast period from 2026 to 2033.
Pheochromocytoma is a neuroendocrine tumor that develops from cells known as chromaffin cells. The adrenal glands contain cells that create hormones that the body needs. The adrenal glands are tiny organs that sit on top of the kidneys in the upper abdomen. The tumor releases hormones that may cause high blood pressure, headache, sweating, and panic attack symptoms. If a pheochromocytoma isn't treated, severe or life-threatening damage to other body systems can result. The treatment consists of anti-hypertensives and surgery.
As per DataM Intelligence, Pheochromocytoma Market study analysis offers an in-depth outlook on the market containing quantitative and qualitative data. It gives an outlook and forecast of the global market based on market segmentation. It also provides global Pheochromocytoma Market size, and growth, along with the latest trends, opportunities, and forecast till 2029 for the global market with esteem to major countries such as the United States, Canada, Brazil, Germany, Italy, Spain, United Kingdom, Russia, European countries, United Arab Emirates, Saudi Arabia, South Africa, Japan, China, India, South Korea, Australia, and rest of the countries over the globe.
Market Scope
| Metrics | Details |
| Market CAGR | 8.5% |
| Segments Covered | By Diagnosis, By Treatment Type, By End-User, By Distribution Channel, and By Region |
| Report Insights Covered | Competitive Landscape Analysis, Company Profile Analysis, Market Size, Share, Growth, Demand, Recent Developments, Mergers and acquisitions, New Product Launches, Growth Strategies, Revenue Analysis, and Other key insights. |
| Fastest Growing Region | Asia Pacific |
| Largest Market Share | North America |
To Know More Insights - Download Sample
Market Dynamics
The pheochromocytoma market is experiencing steady growth, primarily driven by increasing awareness and advancements in diagnostic and treatment technologies. Improved imaging modalities such as CT, MRI, and PET scans, along with enhanced biochemical and genetic testing, have significantly increased early detection rates. Growing adoption of genetic screening for hereditary syndromes linked to pheochromocytoma is further supporting precision medicine approaches. Additionally, the rising prevalence of neuroendocrine tumors and increasing clinical awareness among healthcare professionals are contributing to sustained market expansion.
A key growth driver is the evolution of treatment approaches beyond traditional surgery. While surgical resection remains the primary treatment, the emergence of targeted therapies, radionuclide treatments such as MIBG therapy, and kinase inhibitors is expanding therapeutic options, especially for metastatic or inoperable cases. The integration of multidisciplinary care involving endocrinology, oncology, and nuclear medicine is improving patient outcomes and driving demand for advanced therapeutics. Furthermore, rising investments in rare disease research and increasing availability of specialized care centers are strengthening the market landscape.
However, the market faces several restraints that limit its growth potential. The rarity of pheochromocytoma results in a small patient pool, which restricts large-scale clinical trials and slows drug development. High treatment costs, complex diagnostic procedures, and limited awareness in developing regions further hinder market penetration. Additionally, variability in symptoms often leads to delayed diagnosis, impacting timely treatment. Limited availability of standardized treatment protocols and reimbursement challenges also act as barriers to wider adoption of advanced therapies.
On the opportunity front, the market holds strong potential due to advancements in molecular research and targeted drug development. Innovations such as HIF-2α inhibitors, peptide receptor radionuclide therapy (PRRT), and novel radiopharmaceuticals are creating new growth avenues. Expanding healthcare infrastructure in emerging markets and increasing collaborations between pharmaceutical companies and research institutions are expected to accelerate innovation. Moreover, the growing focus on personalized medicine and real-world evidence-based treatment strategies is likely to unlock new opportunities for long-term market growth.
Key Developments
February 2026: Rising incidence of rare neuroendocrine tumors and increasing adoption of targeted radiopharmaceutical therapies accelerated growth of the pheochromocytoma market across North America and Europe, driven by advanced oncology infrastructure and precision medicine approaches. Key companies active include Novartis (Switzerland), Jazz Pharmaceuticals (Ireland), and Perspective Therapeutics (United States).
January 2026: Regulatory momentum continued with expanded therapeutic approvals such as Merck (United States) advancing oral treatment options like Welireg for adrenal gland tumors, improving access for patients with inoperable or metastatic disease in North America and Europe.
December 2025: Leading pharmaceutical players including Pfizer (United States), Roche (Switzerland), AstraZeneca (United Kingdom), and Bayer (Germany) strengthened their rare oncology portfolios, focusing on adrenal tumor therapies and supportive treatment options across global markets.
November 2025: Increasing utilization of peptide receptor radionuclide therapy (PRRT) and targeted agents such as HIF-2α inhibitors boosted treatment adoption in North America and Europe, where nearly 67% of global demand is concentrated due to strong diagnostic capabilities.
October 2025: Rapid healthcare expansion in Asia-Pacific, especially in China, India, and Japan, improved early detection rates through genetic testing and imaging-based diagnosis, supporting faster market penetration of pheochromocytoma therapies.
September 2025: Growing clinical focus on precision diagnostics and biomarker-based screening strengthened demand for early-stage detection tools in North America and Europe, where hospitals remain the primary end users for treatment and diagnosis.
August 2025: The global pheochromocytoma market reached approximately USD 300 million (7MM, 2025), supported by rising disease awareness, improved imaging techniques, and expanding clinical trial activity across rare tumor therapeutics.
The market is steadily evolving toward targeted therapies, radiopharmaceutical innovation, and precision diagnostics, where North America leads in market share, Europe focuses on clinical advancements, and Asia-Pacific emerges as the fastest-growing region driven by improved healthcare access and increasing diagnostic adoption.
Market Companies
Major key players in the pheochromocytoma market are Septodont, Abbott Laboratories, Jubilant Cadista Pharmaceuticals Inc., Pfizer Inc., ANI Pharmaceuticals, Inc., WellSpring Pharmaceutical Corporation, Valeant Pharmaceuticals North America LLC. Hikma Pharmaceuticals PLC, Progenics Pharmaceuticals, Inc. and Baxter.
Progenics Pharmaceuticals, Inc.:
Overview:
Progenics Pharmaceuticals, Inc., of Tarrytown, N.Y., is a biopharmaceutical company focused on innovative therapeutics for patients who have cancer and related conditions. The company is focused on the development and commercialization of innovative targeted medicines and artificial intelligence to find, fight and follow cancer, including therapeutic agents designed to treat cancer (AZEDRA, 1095, and PSMA TTC); prostate-specific membrane antigen ("PSMA") targeted imaging agents for prostate cancer (PyL and 1404); and imaging analysis technology (aBSI and PSMA AI).
Product Portfolio:
AZEDRA (iobenguane I 131): AZEDRA (iobenguane I 131) is a prescription medicine used to treat adult and pediatric patients 12 years and older with cancers known as pheochromocytoma and paraganglioma that are positive for the norepinephrine transporter (as determined by an iobenguane scan), and who require systemic anticancer therapy.
